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Abstract
Many patients with somatoform disorders are frequently encountered in psychosomatic clinics as
well as in primary care clinics. To assess such patients objectively, the concept of somatosensory
amplification may be useful. Somatosensory amplification refers to the tendency to experience a
somatic sensation as intense, noxious, and disturbing. It may have a role in a variety of medical
conditions characterized by somatic symptoms that are disproportionate to demonstrable organ
pathology. It may also explain some of the variability in somatic symptomatology found among
different patients with the same serious medical disorder. It has been assessed with a self-report
questionnaire, the Somatosensory Amplification Scale. This instrument was developed in a clinical
setting in the U.S., and the reliability and validity of the Japanese and Turkish versions have been
confirmed as well.
Many studies have attempted to clarify the specific role of somatosensory amplification as a
pathogenic mechanism in somatization. It has been reported that somatosensory amplification does
not correlate with heightened sensitivity to bodily sensations and that emotional reactivity exerts
its influence on somatization via a negatively biased reporting style. According to our recent
electroencephalographic study, somatosensory amplification appears to reflect some aspects of
long-latency cognitive processing rather than short-latency interoceptive sensitivity.
The concept of somatosensory amplification can be useful as an indicator of somatization in the
therapy of a broad range of disorders, from impaired self-awareness to various psychiatric
disorders. It also provides useful information for choosing appropriate pharmacological or
psychological therapy. While somatosensory amplification has a role in the presentation of somatic
symptoms, it is closely associated with other factors, namely, anxiety, depression, and alexithymia
that may also influence the same. The specific role of somatosensory amplification with regard to
both neurological and psychological function should be clarified in future studies. In this paper, we
will explain the concept of amplification and describe its role in psychosomatic illness.
Assessment of stress-related conditions
Stress is the term used to define the body's physiological
and/or psychological reaction to circumstances that
require behavioral adjustment. According to the Japanese
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National Survey of Health in 2004 [1], 49% of those 12
years or older reported experiencing stress in their daily
lives. In this survey, the subjects answered "yes" if they
perceived stress in any of 28 domains including work,
family and neighborhood relations as well as living-,
social-, financial-, and health-related situations. A higher
percentage of perceived stress was observed in women
(53%) than in men (45%); the percentage of perceived
stress has continued to increase over the years. in both
sexes. Work-related problems were the most frequent
stressors, followed by health-related and then financial
problems [1]. One of the interesting findings of this
national survey[1] was that stress was more frequently
reported by those complaining of any physical or psycho-
logical symptoms; 69% of 37 million people with such
symptoms reported stress as opposed to only 39% of 75
million people without symptoms who did (p < 0.0001,
chi-square test). These results [1] suggest that those per-
ceiving psychosocial stress are also likely to complain of
mind/body symptoms.
The symptoms related to psychosocial stress are often
temporary and disappear with the relief of such stress.
However, a specific illness may be caused when the expe-
rienced stressors are too intense and persistent. When
people are vulnerable to stress because of their character
and ability to adapt, a psychosomatic illness is likely to
occur even if the stressors are mild or moderate[2]. The
Japanese Society of Psychosomatic Medicine defines psy-
chosomatic illness as any physical condition with organic
or functional damage affected by psychosocial factors in
its onset or development[3]. This definition largely corre-
sponds to that of "psychosocial factors affecting general
medical conditions (code 316.00)" of the Diagnostic and
Statistical Manual of Mental Disorders fourth edition, text
revision (DSM-IV-TR) [4], published by the American Psy-
chiatric Association.
Somatization and psychosomatic illness
According to a study[5] of outpatients visiting a Japanese
psychosomatic clinic (n = 1,432), the most common
physical disorders observed were autonomic nervous dys-
function, irritable bowel syndrome, essential hyperten-
sion, and hyperventilation. Eating disorders, anxiety
disorders, and depressive episodes were also prevalent.
When the DSM-III-R or DSM-IV criteria were applied to
the total sample, "somatoform disorders not otherwise
specified" became the most common diagnosis, followed
by bulimia nervosa, depressive disorders not otherwise
specified, anorexia nervosa, conversion disorder, major
depression or depressive disorder, panic disorder with
agoraphobia, and psychological factors affecting physical
(or medical) condition.
These findings appear to conflict with those from Western
countries[6,7]. For example, a study in an Italian psycho-
somatic clinic [6] showed that the most frequent diagno-
sis was "psychological factors affecting physical
condition," followed by affective illness, anxiety distur-
bance, and somatoform disorders according to the DSM-
III criteria. In a Japanese study[5], a detailed manual of
diagnoses was made, and the physicians specializing in
psychosomatic medicine discussed the patients' diagnoses
in order to improve the reliability of diagnoses; however,
many patients were still categorized into "somatoform
disorders not otherwise specified." These studies indicate
that there is considerable confusion and ambiguity in
diagnosing patients with somatization. To assess such
patients more objectively, the concept of somatosensory
amplification may be useful in clinical practices.
Concept of somatosensory amplification
Somatosensory amplification refers to the tendency to
experience a somatic sensation as intense, noxious, and
disturbing [8]. The construct of somatosensory amplifica-
tion is helpful in the assessment of somatization and in
the conceptualization of psychosomatic illness [8-10].
Somatosensory amplification may have a role in a variety
of medical conditions characterized by somatic symptoms
that are disproportionate to demonstrable organ pathol-
ogy. It may also explain some of the variability in somatic
symptomatology found among different patients with the
same serious nonpsychiatric medical disorder.
Studies of amplification in patients with somatoform dis-
orders have been conducted. These studies have resulted
in the standardization of the Somatosensory Amplifica-
tion Scale (SSAS) checklist in 1990 [11]. (Table 1) The
original SSAS[11] was developed in a clinical setting in the
U.S., and the reliability and validity of the Japanese[12]
and Turkish forms[13] of the SSAS have been confirmed
as well. It is a 10-item self-report questionnaire, and the
respondents rate the degree to which each statement is
''characteristic of you in general,'' on an ordinal scale of 1
Table 1: Somatosensory Amplification Scale
1. When someone else coughs, it makes me cough too.
2. I can't stand smoke, smog, or pollutants in the air.
3. I am often aware of various things happening within my body.
4. When I bruise myself, it stays noticeable for a long time.
5. Sudden loud noises really bother me.
6. I can sometimes hear my pulse or my heartbeat throbbing in 
my ear.
7. I hate to be too hot or too cold.
8. I am quick to sense the hunger contractions in my stomach.
9. Even something minor, like an insect bite or a splinter, really 
bothers me.
10. I have a low tolerance for pain.BioPsychoSocial Medicine 2007, 1:17 http://www.bpsmedicine.com/content/1/1/17
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to 5. A higher total score indicates greater symptom ampli-
fication (score range of 10 to 50).
According to our clinical experiences and previous studies
targeting the Japanese population, SSAS scores over 30
may reflect a highly somatizing condition; the average
SSAS scores were 24–29 in groups of university stu-
dents[14], office workers[15], and outpatients visiting a
general internal medicine clinic [10] whereas it was 32 in
the patients visiting a psychosomatic clinic[10]. Based on
such experimental and epidemiological studies, we
believe that somatosensory amplification appears to have
both trait-like and state-like properties[10,14,15].
The SSAS is useful in briefly and objectively evaluating
patients with mind/body distress. The total number of
reported somatic symptoms has been considered to be a
powerful predictor of functional impairment in physical,
psychological, and social functioning [16], and the SSAS
scores were shown to be closely associated with the total
number of somatic symptoms in patients visiting a psy-
chosomatic clinic[10].
Somatosensory amplification and alexithymia
Alexithymia is a personality construct derived from the
clinical observation of patients with psychosomatic ill-
ness [17]. It is characterized by difficulty in distinguishing
between emotions and bodily sensations, difficulty iden-
tifying and describing emotions, and a mechanistic, con-
crete, literal cognitive style. Evidence has suggested that
alexithymia is associated with a tendency to develop func-
tional somatic symptoms [18-20]. Our recent study
reported that the SSAS was significantly correlated with a
Toronto Alexithymia Scale (TAS), in the sample of indi-
viduals with psychosomatic illness[10]. High rates of alex-
ithymia have been reported in patients with essential
hypertension, myocardial infarction, inflammatory bowel
diseases, functional gastrointestinal disorders, and
chronic pain [21], and the close relationship between
alexithymia and somatosensory amplification has been
demonstrated in chronic pain [22] and functional dyspep-
sia[23]. The statistical and clinical association between
somatosensory amplification and alexithymic characteris-
tics appears logical. The roles of these two psychological
concepts in clinical conditions should be further studied
to clarify symptom generation and perception in patients
with psychosomatic illness.
Role of somatosensory amplification
Three components of somatosensory amplification have
been described[24]: bodily hypervigilance that involves
heightened self-scrutiny and increased attention to
unpleasant bodily sensations; the tendency to select and
focus on certain relatively weak or infrequent sensations;
and the tendency to appraise ambiguous or vague visceral
and somatic sensations as abnormal, pathological, and
symptomatic of disease, rather than considering them to
be normal. This cognitive appraisal causes alarm and anx-
iety in relation to the perception of symptoms and is pro-
posed to act as the intermediary between the perception of
bodily sensations on one hand and hypochondriacal
beliefs and behaviors on the other. Many studies have
attempted to clarify the specific role of somatosensory
amplification as a pathogenic mechanism in somatization
[25-27]. A recent study[28] failed to find a significant rela-
tionship between the SSAS and heartbeat detection ability
and interoceptive sensitivity, suggesting that self-reported
somatosensory amplification does not correlate with
objectively measured sensitivity to bodily sensations. In
another study[29], emotional reactivity appeared to exert
its influence on somatization via a negatively biased
reporting style and not via somatic sensitivity.
To elucidate the link between somatosensory amplifica-
tion and sensitivity to bodily sensations, we conducted an
electroencephalographic (EEG)[14] study in 33 university
students examining the relationship between somatosen-
sory amplification and four different types of evoked
potentials, i.e., short-latency somatosensory evoked
potential (SSEP), brainstem auditory-evoked potential
(BAEP), visual evoked potential (VEP), and auditory
event-related potential (ERP). (Figure 1) We found that
the SSAS was significantly associated with the parameters
of auditory ERP (i.e., the P200 latency and P300 ampli-
tude) after adjusting for the effects of the TAS and of the
depression and tension-anxiety subscales of the Profile of
Mood States[14].(Table 2) This significant relationship
between the SSAS and auditory ERP appears important.
The SSEP (normally 8.0–30.0 ms in latency) reflects
mechanical processing in short pathways from sensory-
organ to the primary cortex, whereas auditory ERP (nor-
mally 100–350 ms in latency) reflects cognitive process-
ing of bodily sensations which they operationally define
as processing in long pathways from the sensory-organ to
cerebral cortex via complex synaptic circuits[30,31]. Based
on the insignificant findings of SSEP in the study[14], the
SSAS was not suggested to be a measure of mechanical
conduction from the sensory organs to the first sensory
cortex areas. Rather the SSAS seems to be more closely
related to the processing of sensory input at higher level of
central nervous system. Auditory ERP is divided into early-
(<100 ms) and late- (>100 ms) occurring components
[30,31]. The late component represents aspects of infor-
mation processing, such as attention allocation and acti-
vation of immediate memory, while the early component
represents the activity of the sensory nerves, brainstem,
and primary sensory cortex. Thus a delayed P200 and
diminished P300 amplitude may reflect a disturbance in
the awareness of or the attention paid to afferent stimuli
due to abnormally increased levels of physiological inhi-BioPsychoSocial Medicine 2007, 1:17 http://www.bpsmedicine.com/content/1/1/17
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bition, possibly at the level of the brainstem, cortex, or
both [32,33]. Although the findings [14] should be
viewed as preliminary, somatosensory amplification
appears to reflect some aspects of long-latency cognitive
processing rather than short-latency interoceptive sensi-
tivity from the viewpoint of EEG.
Use of SSAS
The concept of somatosensory amplification enables us to
quantify the intensity of various somatic symptoms that
patients complain about, eliminating the subjective judg-
ment of physicians. The objective measurement of soma-
tosensory sensitivity with a psychophysiological
instrument is difficult and time consuming. The SSAS is
simple and requires less than 10 min to complete.
Although there are many reliable questionnaires for
assessing somatoform symptoms, such as the Whitely
Index, Somatic Symptom Inventory, the hypochondriasis
subscale on the Minnesota Multiphasic Personality Inven-
tory, and the somatization scale on the Symptom Check-
list 90R [34-37], the SSAS enables the evaluation of
somatosensory amplification in various diseases with
fewer questions.
The SSAS should be used in combination with other psy-
chological questionnaires in a test battery. This is because
mood states, psychosocial stress, and the number of
somatic symptoms can all influence somatosensory
amplification as shown previously[10]. The choice of
additional instruments will vary depending on the study
aims; however, at least mood states and the severity of
somatic impairment should be evaluated.
The SSAS can be useful as an indicator of somatization in
the therapy of a broad range of disorders, from impaired
self-awareness [37-39] to various psychiatric disor-
ders[40,41]. The concept of somatosensory amplification
helps patients and physicians to better understand situa-
tions in which the psychiatric symptoms do not match the
patients' clinical conditions and also provide useful infor-
mation for choosing the appropriate pharmacological or
psychological therapy. The SSAS would be useful in the
treatment of patients with specific psychosomatic illness
(e.g., irritable bowel syndrome[37,42,43] and chronic
pain[22,44-46]), psychiatric disorders (e.g., somatoform
disorders [47-52], anxiety disorders[53,54], and mood
disorders[50,55]), stress reaction (e.g., reaction to
bereavement[56] and other important psychosocial
events[55]), and medical disorders (e.g., infectious dis-
ease[56] and heart disease[57,58]).
Conclusion
A total of 50 English-language articles[8,10,11,13-
15,20,22-29,33-55,57-68] were identified using the text
words "somatosensory amplification" through a
MEDLINE search from 1966 to April 2007. Somatization
is a common feature in patients with mind/body distress,
and the concept of somatosensory amplification provides
a new approach to psychosomatic research [69-71]. It can
help us to identify the explicit factors mediating the links
between somatic and psychological symptoms. While
somatosensory amplification has a role in the presenta-
tion of somatic symptoms, it is closely associated with
other factors, namely, anxiety, depression, and alex-
ithymia that may also influence the same. The specific role
of somatosensory amplification with regard to both neu-
rological and psychological function should be clarified
in future studies.
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BAEP: Bainstem auditory-evoked potential.
DSM-III: Diagnostic and statistical manual of mental dis-
orders, third edition.
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Table 2: Evoked potentials associated with the SSAS
EEG variables Means (S.D.) and coefficienta to SSAS 
(signed)
Latency, msec Amplitude, µV
Somatosensory 
evoked potential
N9 9.5 (0.7) (+) 5.1 (2.3) (-)
N9–N13 3.8 (0.6) (+) 1.8 (0.8) (-)
N13–N20 5.8 (1.2) (-) 1.1 (0.7) (+)
N20–P23 3.3 (1.2) (-) 1.2 (0.7) (+)
Auditory evoked 
potential
I 1.5 (0.1) (+) 0.2 (0.1) (-)
III 3.7 (0.1) (-) 0.3 (0.1) (-)
V 5.6 (0.2) (+) 0.6 (1.3) (-)*
Visual evoked potential
N75 73.2 (10.1) (-) 3.3 (2.3) (-)
P100 103.1 (10.3) (+)* 5.9 (2.3) (-)
N145 138.0 (15.9) (-) 3.3 (1.7) (-)
Event-related potential
N100 111.5 (40.6) (+) 4.2 (2.1) (-)
P200 180.3 (45.2) (+)** 2.9 (1.6) (+)
N200 248.1 (51.7) (+) 4.4 (2.9) (-)
P300 333.6 (70.7) (+) 2.7 (1.8) (-)**
a The coefficient refers to the partial Pearson's correlation coefficient 
adjusted for the Toronto alexithymia scale scores and depression and 
tension-anxiety scores on the Profile of Mood States. A positive 
(negative) mark indicates a positive (negative) coefficient; *p < 0.10 
and **p < 0.05.BioPsychoSocial Medicine 2007, 1:17 http://www.bpsmedicine.com/content/1/1/17
Page 5 of 7
(page number not for citation purposes)
DSM-IV-TR: Diagnostic and statistical manual of mental
disorders, fourth edition, text revision.
EEG: Electroencephalography.
ERP: Event-related potential.
SD: Standard deviation.
SSAS: Somatosensory amplification scale.
SSEP: Short-latency somatosensory evoked potential.
TAS: Tronto Alexithymia Scale
VEP: Visual evoked potential.
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